

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/763,974
	Filing Date	January 22, 2004
	First Named Inventor	Hassan PAJOUHESH
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	12 + 70 Refs	Attorney Docket Number 381092001600

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form 1449, 4 pages in duplicate; (70) References; Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement, 3 pgs	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<b>CUSTOMER NO. 25225</b>	

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	MORRISON & FOERSTER LLP Emily C. Tongco - 46,473
Signature	
Date	March 15, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3-15-2004 Signature: Rhea Amid (Rhea Amid)



PATENT  
Docket No. 381092001600

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on March 15, 2004.

  
Rhea Amid

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Hassan PAJOUHESH et al.

Serial No.: 10/763,974

Filing Date: January 22, 2004

For: N-TYPE CALCIUM CHANNEL  
BLOCKERS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 381092001600. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 15, 2004

Respectfully submitted,

By:   
Emily Tongco  
Registration No. 46,473

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 314-5413  
Facsimile: (858) 720-5125



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number 381092001600	Application Number 10/763,974
	Applicant Hassan PAJOUHESH et al.	
	Filing Date January 22, 2004	Group Art Unit To Be Assigned
	Mailing Date March <u>15</u> 2004	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	11/1988	4,785,119	Hojo et al.	548	557	
	2.	06/1995	5,428,038	Chatterjee et al.	514	253	
	3.	04/1997	5,624,677	El-Rashidy et al.	424	435	
	4.	07/1997	5,646,149	Hellberg et al.	514	253	
	5.	12/1997	5,703,071	Itoh et al.	514	218	
	6.	01/2000	6,011,035	Snutch et al.	514	231.2	
	7.	09/2001	6,294,533	Snutch et al.	514	231.2	
	8.	10/2001	6,310,059	Snutch	514	222.2	
	9.	02/2002	6,348,600	Ono et al.	548	545	
	10.	05/2002	6,387,897	Snutch	514	231.2	
	11.	10/2002	6,468,998	Kuroita et al.	514	214.03	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	12.	07/1972	GB 1,281,188	Great Britain			
	13.	04/1998	WO 98/17625	WIPO			Abstract

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	14.	Augustine et al., Annu Rev Neurosci (1987) 10:633-693
	15.	Backonja et al., JAMA (1998) 280:1831-1836
	16.	Bourinet et al., Nature Neuroscience (1999) 2:407-415
	17.	Bowersox, J Pharmacol Exp Ther, (1996) 279:1243-1249

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Docket Number 381092001600	Application Number 10/763,974
		Applicant  Hassan PAJOUHESH et al.	
		Filing Date January 22, 2004	Group Art Unit To Be Assigned
		Mailing Date March <u>6</u> , 2004	
	18.	Caraceni et al., J Pain & Symp Manag (1999) 17:441-445	
	19.	Catterall, Annu Rev Cell Dev Biol (2000) 16:521-55	
	20.	Cesena and Calcutt, N.A. Neurosci Lett (1999) 262:101-104	
	21.	Chaplan et al., J Pharmacol Exp Ther (1994) 269:1117-1123	
	22.	Cheng et al., Anesthesiology (2000) 92:1126-1131	
	23.	Corruble et al., Tetrahedron: Asymmetry (1997) 8(10): 1519-1523	
	24.	Corruble et al., Journal of the American Chemical Society (1997) 119(42): 10042-10048	
	25.	Cribbs et al., Circulation Research (1998) 83:103-109	
	26.	De Waard et al., (1996) Structural and functional diversity of voltage activated calcium channels. In: Narahashi (ed.) Ion Channels, Plenum Press, NY	
	27.	Di Trapani et al., Clin Ter (2000) 151:145-148	
	28.	Dooley, Current Opinion in CPNS Investigational Drugs (1999) 1:116-125	
	29.	Dubel et al., Proc. Natl. Acad. Sci. USA (1992) 89:5058-5062	
	30.	Dunlap et al., Trends Neurosci (1995) 18:89-98	
	31.	Field et al., Pain (1999) 80:391-398	
	32.	Fujita et al., Neuron (1993) 10:585-598	
	33.	Gomora et al., Mol Pharmacol (2001) 60:1121-1132	
	34.	Gould et al., Proc Natl Acad Sci USA (1983) 80:5122-5125	
	35.	Grantham et al., Brit J Pharmacol (1944) 111:483-488	
	36.	Hatakeyama et al., NeuroReport (2001) 12:2423-2427	
	37.	Heading, Curr Opin CPNS Investigational Drugs (1999) 1:153-166	
	38.	Houtchens, Multiple Sclerosis (1997) 3:250-253	
	39.	Huguenard, Annu Rev Physiol (1996) 58:329-348	
	40.	Ino et al., Proc. Natl. Acad. Sci. USA (2001) 98:5323-5328	
	41.	Janis and Triggle, In: Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance (1991) CRC Press, London	
	42.	Jones, Eur J Pharmacol (2002) 447:211-225	
	43.	Kim et al., Mol Cell Neurosci (2001) 18:235-245	
	44.	Kim et al., Neuron (2001) 31:35-45	
	45.	King et al., J Biol Chem (1989) 264:5633-5641	
	46.	Laird and Gidal, Annal Pharmacotherap (2000) 34:802-807	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

<b>Form PTO-1449</b> <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b>		Docket Number 381092001600	Application Number 10/763,974
		Applicant Hassan PAJOUHESH et al.	
		Filing Date January 22, 2004	Group Art Unit To Be Assigned
		Mailing Date March 15, 2004	
	47.	Lee et al., Neuroscience (1999) 19:1912-1921	
	48.	Magnus, Epilepsia (1999) 40(Suppl 6):S66-S72	
	49.	Malmberg and Yaksh, J Neurosci (1994) 14:4882-4890	
	50.	Mathur, Seminars in Anesthesia, Perioperative medicine and Pain (2000) 19:67-75	
	51.	McCleskey and Schroeder, Cur Topics Membr (1991) 39:295-326	
	52.	McRory et al., J Biol Chem (2001) 276:3999-4011	
	53.	Mikami et al., Nature (1989) 340:230-233	
	54.	Miller, Science (1987) 235:46-52	
	55.	Mori et al., Nature (1991) 350:398-402	
	56.	Nicholson, Acta Neurol Scand (2000) 101:359-371	
	57.	Penn and Paice, Pain (2000) 85:291-296	
	58.	Perez-Reyes et al., Nature (1998) 391:896-900	
	59.	Perez-Reyes, Physiol Rev (2003) 83:117-161	
	60.	Prigent et al., Journal de Chimie Physique et de Physico-Chimie Biologique (1998) 95(2): 401-405	
	61.	Ridgeway et al., Pain (2000) 85:287-289	
	62.	Rowbotham et al., JAMA (1998) 280:1837-1842	
	63.	Saegusa et al., Proc. Natl. Acad. Sci. USA (2000) 97:6132-6137	
	64.	Salemme et al., Structure (1997) 5:319-324	
	65.	Santi et al., J Neurosci (2002) 22:396-403	
	66.	Sather et al., Neuron (1993) 11:291-303	
	67.	Sluka, J Pharmacol Exp Ther (1998) 287:232-237	
	68.	Snutch, et al., Neuron (1991) 7:45-57	
	69.	Soong, et al., Science (1993) 260:1133-1136	
	70.	Stea et al., Voltage-gated calcium channels. In: Handbook on Ion Channels. North (ed.) CRC Press, pp. 113-151 (1994)	
	71.	Stea et al., Proc. Natl. Acad. Sci. USA (1994) 91:10576-10580	
	72.	Su et al., J Neurosci (2002) 22:3645-3655	
	73.	Taylor et al., Epilepsy Res (1998) 29:233-249	
	74.	Tomlinson et al., Neuropharmacology (1993) 32:1117-1126	
	75.	Tumilowicz et al., Cancer Res (1970) 30(8):2110-2118	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number 381092001600	Application Number 10/763,974
	Applicant Hassan PAJOUHESH et al.	
	Filing Date January 22, 2004	Group Art Unit To Be Assigned
	Mailing Date March 12, 2004	

	76.	Vanegas and Schaible, Pain (2000) 85:9-18
	77.	Wade, Organic Chemistry (1987) pages 333-398, Prentice-Hall, Inc., Englewood Cliffs, New Jersey
	78.	Wang et al., Soc Neurosci Abstr (1998) 24:1626
	79.	Wentworth and Janda, Curr Opin Biotechnol (1998) 9:109-115
	80.	Williams, Science (1992) 257:389-395
	81.	Williams, Neuron (1992) 8:71-84

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	